OCT 21, 2026 · JOURNAL ARTICLE
Advancing to Phase 3: Maridebart Cafraglutide’s Once-Monthly Profile in Obesity—Mechanisms, Outcomes, and Competitive Landscape
Pain Joints Spine
Background: Obesity, affecting approximately 40% of adults globally, remains inadequately managed by current pharmacotherapies, with most medications achieving weight loss plateaus